Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Women's Healthcare Tailored to you Women's Healthcare Tailored to you

Women's Healthcare
Tailored to you

Research

Two young women chating & looking at a laptop on a table in a comfortable, naturally lit apartment / home.

At ChristianaCare, we pride ourselves on being at the forefront of all things medical – including publishing and following all of the latest research so that both our experts and patients can stay informed and confident in their choices.

View Clinical Trials

OB/GYN Research

ChristianaCare is a regional leader in obstetrics and maternal fetal medicine research and is a member of the National Institute of Child Health and Human Development’s Maternal Fetal Medicine Unit Network. The network focuses on clinical questions in maternal fetal medicine and obstetrics, particularly with respect to the continuing problem of preterm birth.

Ob/Gyn research at ChristianaCare focuses on the following health concerns for newborns and new mothers:

Preventing preterm birth. Identifying normal fetal growth standards. Understanding the cause of child development disorders. Research efforts are supported by the staff and resources of ChristianaCare, one of the nation’s top providers of obstetric services and one of the largest and most experienced maternity centers and neonatal intensive care units in the Delaware Valley.

Cancer Clinical Trials

ChristianaCare’s Cancer Research Program is part of a select group of 46 research centers (34 community sites and 12 minority/under-served sites) in the United States and Puerto Rico that are funded by the National Cancer Institute to participate in the NCI Community Oncology Research Program (NCORP). Thousands of patients throughout the Delaware region have benefited from studies conducted under the auspices of the NCORP, as well as from a variety of other federally funded and industry-supported cancer treatment, prevention and control trials. Many of these trials take place on a national or international level at approved research centers around the country and throughout the world.

ChristianaCare also takes part in NCI-funded Cancer Care Delivery Research (CCOR) which is focused on patient, provider and organizational -level influences on cancer outcomes.

Clinical trials test new drugs and combinations of treatments, as well as new techniques using surgery, radiation therapy, gene therapy, immunotherapy and biologics. Research studies encompass a wide range of cancer-related disciplines including hematology/oncology, radiation oncology and gynecologic oncology.

Clinical trials offered by ChristianaCare attract participants from Delaware, New Jersey, Maryland and Pennsylvania. Delaware research affiliates that include Beebe Healthcare, Tunnell Cancer Center and Nanticoke Health Services Cancer Care Center participate in NCI research. Our annual accrual rate—which measures the percentage of patients enrolled in clinical trials—among newly diagnosed cancer patients is among the highest in the nation. At any given time, we have at least 700 patients enrolled in as many as 100 different clinical trials.

All studies are first approved by the National Cancer Institute Central Institutional Review Board and/or ChristianaCare’s Institutional Review Board, a special committee that reviews and oversees all research projects to ensure that participants’ rights and welfare are protected.

Diabetes & Metabolic Diseases Research

ChristianaCare’s Diabetes & Metabolic Diseases Research Program is part of the ChristianaCare Research Institute and has participated in more than 100 clinical trials involving inpatients and outpatients. The research has covered various aspects and phases of diabetes-related illnesses and treatments, including:

  • Treatment modalities.
  • New medications.
  • Devices.
  • Foot ulcers.
  • Neuropathy.
  • Gastroparesis.
  • Retinopathy.

The program staff is made up of two nationally certified research coordinators, a full-time recruiter, experienced physicians specializing in endocrinology, a Ph.D.-level research scientist and diabetes educators.